Figure 1.

Figure 1 shows T cell therapies targeting melanoma. Tumor may be harvested and tumor infiltrating lymphocytes harvested and cultured for subsequent infusion to the patient (1A). Peripheral blood mononuclear cells may be genetically modified with a chimeric antigen receptor (shown) or a T cell receptors specific for an antigen expressed by tumor cells (1B). Peripheral blood mononuclear cells may be stimulated with peptides derived from a tumor antigen expressed on antigen presenting cells to generate T cell clones which recognize tumor antigens (1C)